Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?

ABSTRACT: Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting

SUBMITTER: Alexander H 

PROVIDER: S-EPMC6357995 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature